exaibio
Precision Medicine · Molecular Diagnostics
$70.6Mlatest round · Venture round · Sep 2021 · 5 yr ago
$1.3Mgrants · 1 grant · CORDIS
200+team · employees, estimated range
2021founded
Overview
EX MARKS THE SPOT, AI CRACKS THE CODE. Exai is harnessing RNA for early, accurate cancer detection and profound insights from just a blood sample.
Funding and backers
Total raised
$70.6M
2 rounds on record
Latest round
$70.6M
Venture round · Sep 2021 · 5 yr ago
Team
201-500
employees, estimated range
Grants
$1.3M
1 grant · CORDIS
The money's age
Long since its last round
61 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 12, 2024
Won a grant $1.3M · CORDIS
Sep 23, 2021
Raised a round Venture round $70.6M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2024 | $1.3M | — | CORDIS |
| Venture round | Sep 2021 | $70.6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Exai Bio Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Patrick ArensdorfExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Liquid biopsy for the early detection of gastric cancer. With only a blood sample, and even without symptoms, detects a tumor in the…
Combining the power of liquid biopsy and AI-driven epigenetics, we deliver accurate cancer detection. Our approach transforms diagnostics…
Early detection of cancer starts with knowing who is at risk. Elypta provides the missing dynamic biological signal that unlocks risk…
Biomarx delivers rapid, low-cost, fully automated liquid biopsy — genomic-grade cancer answers from a blood test in under 2 hours, starting…
InterVenn is a biotechnology company that develops glycoproteomics technology to read a clinical layer of biology beyond the genome from a…
Valius Sciences is a diagnostics and bioinformatics company building comprehensive DNA, RNA and protein assessments of tumors for cancer…
People
Patrick Arensdorf
Executive Officer, Director
Alexander Parker
Director
Hani Goodarzi
Director
Michael Pellini
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform
Read more
Report
Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai
/PRNewswire/ -- Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative (QLHC) to broaden the use of Exai
Read more
Report
Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer
Read more
Report
Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer
Read more
Report
Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer
Read more
Report
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Palo Alto
United States
HQ
innovation knows no borders.
200-500 est. staff
3350 west bayshore road, palo alto, california 94303